JS
Jasper Therapeutics, Inc.
JSPRW · NASDAQ
$0.01 -93.75% (-$0.08)
1M -58.68%
Market Cap $81.3K
P/E Ratio -
Div. Yield -
ROE 618.87%
Bulios Fair Price
$0.01
100.0% upside
Current Price
$0.005
Undervalued Fair Value Overvalued
According to Bulios Fair Price, JSPRW is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
100 /100
Cheap P/B 0.06x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining Book val. growth 51.32%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
FCF margin N/A
Quality
0 /100
Poor ROIC 1,305.04%
ROE 618.87%
Asset turnover 0.00x
Debt
91 /100
Low Debt/Equity 0.19x
Current ratio 1.47x
Int. coverage N/A
Stability
44 /100
Moderate Beta 3.01x
EPS volatility 11.65%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about JSPRW
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jeetinder Singh Mahal
Employees
22
Headquarters
Redwood City
Upcoming events
05 NOV
Earnings
Upcoming earnings report